Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.66 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | HTR1E | P28566 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.48 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3821416 | 1.00 | AKR1C1 (0.66) | AKR1C1MEN1KMT2ATSHRCYP2C19 | |
| SCHEMBL1048151 | 0.98 | AKR1C1 (0.68) | AKR1C1MEN1KMT2ATSHRCYP2C19 | |
| SCHEMBL3485961 | 0.94 | AKR1C1 (0.62) | AKR1C1MEN1KMT2ATSHRCYP2C19 | |
| SCHEMBL351393 | 0.90 | AKR1C1 (0.55) | AKR1C1MEN1KMT2ATSHRCYP2C19 | |
| SCHEMBL15912397 | 0.85 | CYP2C19 (0.50) | AKR1C1MEN1KMT2ATSHRCYP2C19 | |
| SCHEMBL9577294 | 0.83 | AKR1C1 (0.48) | AKR1C1MEN1KMT2ATSHRMAPT | |
| SCHEMBL4810246 | 0.83 | MAPT (0.47) | AKR1C1MEN1KMT2ATSHRMAPT | |
| SCHEMBL9685778 | 0.83 | CYP2C19 (0.49) | AKR1C1MEN1KMT2ATSHRCYP2C19 | |
| SCHEMBL4992446 | 0.83 | LMNA (0.59) | AKR1C1MEN1KMT2ATSHRMAPT | |
| SCHEMBL2443314 | 0.82 | MAPT (0.49) | AKR1C1MEN1KMT2ATSHRMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114790136-A | Preparation method and application of active trivalent organic chromium compound | 中国石油天然气股份有限公司 | 2022-07-26 | — | — | CN | claimed |
| EP-3515880-B1 | METHODS AND COMPOSITIONS FOR SYNTHESIS OF ENCODED LIBRARIES | HITGEN INC (CN) | 2023-05-10 | — | — | EP | disclosed |
| CN-114790136-A | Preparation method and application of active trivalent organic chromium compound | 中国石油天然气股份有限公司 | 2022-07-26 | — | — | CN | disclosed |
| US-20200149034-A1 | Methods and Compositions for Synthesis of Encoded Libraries | HITGEN INC. (CN) | 2020-05-14 | — | — | US | disclosed |
| CN-105899507-B | Aryl sultam derivative as RORc regulator | 豪夫迈·罗氏有限公司 | 2019-06-07 | — | — | CN | disclosed |
| CN-105899507-A | Aryl sultam derivatives as rorc modulators | 豪夫迈·罗氏有限公司 | 2016-08-24 | — | — | CN | disclosed |
| EP-2718280-B1 | COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | CHIESI FARMA SPA (IT) | 2015-09-16 | — | — | EP | disclosed |
| US-8877774-B2 | Compounds having muscarinic receptor antagonist and beta2 Adrenergic receptor agonist activity | CHIESI FARMACEUTICI S.P.A. (IT) | 2014-11-04 | — | — | US | disclosed |
| EP-2718280-A1 | COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | Chiesi Farmaceutici S.p.A. (IT) | 2014-04-16 | — | — | EP | disclosed |
| CN-103562198-A | Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity | CHIESI FARMA SPA | 2014-02-05 | — | — | CN | disclosed |
| US-6984642-B1 | Substituted phenylcyclohexane carboxylic acid amides and their use as adenosine uptake inhibitors | BAYER AKTIENGESELLSCHAFT (DE) | 2006-01-10 | — | — | US | disclosed |
| US-20050234106-A1 | Cycloalkyl inhibitors of potassium channel function | LLOYD JOHN | 2005-10-20 | — | — | US | disclosed |
| EP-1583736-A1 | CARBAMIC ACID COMPOUNDS COMPRISING AN ESTER OR KETONE LINKAGE AS HDAC INHIBITORS | TopoTarget UK Limited (GB) | 2005-10-12 | — | — | EP | disclosed |
| WO-2004065354-A1 | CARBAMIC ACID COMPOUNDS COMPRISING AN ESTER OR KETONE LINKAGE AS HDAC INHIBITORS | TOPOTARGET UK LIMITED (GB) | 2004-08-05 | — | — | WO | disclosed |
| EP-1091958-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2001-04-18 | — | — | EP | disclosed |
| WO-2000001692-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2000-01-13 | — | — | WO | disclosed |
| EP-0564924-B1 | 2-Oxoethyl derivatives as immunosuppressants | BAYER AG (US) | 1998-09-09 | — | — | EP | disclosed |
| US-5686424-A | FOR TREATING INFLAMMATION | MILES INC. (US) | 1997-11-11 | — | — | US | disclosed |
| EP-0564924-A2 | 2-Oxoethyl derivatives as immunosuppressants | Bayer Corporation (US) | 1993-10-13 | — | — | EP | disclosed |
| US-4247597-A | Electroscopic carrier particles having a carboxylic acid surface treatment | PITNEY BOWES, INC. (US) | 1981-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050234106-A1 | Cycloalkyl inhibitors of potassium channel function | KCNJ2, KCNN3, KCNQ5 | AKR1C1 1009/4885MEN1 4430/4885KMT2A 1396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.